Dr. Graham Love:

I will pick up on the key point arising from Senator Robbie Gallagher's question. The paper presented to the committee today is the product of a round table meeting of key stakeholders which took place last November. We will commit to running that again in the near term and I would suggest that this committee invites us back to relay the outcome of that round table. We are getting more clarity here. While it is still not absolutely clear, we are gaining clarity on the Brexit situation.

To pick up on the capital versus recurrent issue, it is difficult not to say "both". Capacity issues were a key theme here today. There is certainly a need for some basic level of capital investment to allow the human capital that we need flow through the system.

Third, several people mentioned INTERREG. A week and a half ago, while I was still in my previous job as head of the Health Research Board, I signed off on a €9 million deal for clinical trials in the community in the Border counties, which will give access to people in the community to medicines and medical devices and put Ireland further onto that innovation map that is the product of the INTERREG programme. It will be €5 million to the North and €3.5 million to the South. I reiterate the key need to keep access to that type of funding.